Founded by Milan Puskar and Don Panoz as Milan Pharmaceuticals in 1961, Mylan incorporated in Pennsylvania and went public on the NASDAQ in 1973. The company produces and markets numerous generic and proprietary (brand name) drugs. The company's pharmaceutical products include antibiotics, antidepressants, anti-inflammatories, beta-blockers, and laxatives. Mylan has more than 570 medicines it sells to wholesalers, distributors, retail drugstore chains, and government agencies. The company's Matrix division is the one of the world's largest producers of active pharmaceutical ingredients (API) for generic drugs. Headquartered in Canonsburg, Pennsylvania, the company has operations in more than 140 countries and territories including research and development laboratories and manufacturing facilities in West Virginia, Puerto Rico, Texas, Vermont, and Illinois, and a distribution center in North Carolina and internationally in include India, Europe, China and South Africa. Mylan's generic operations are through 2 principal subsidiaries, Mylan Pharmaceuticals Inc. and UDL Laboratories, Inc., while the company has branded segment operates through Bertek Pharmaceuticals Inc. and Mylan Technologies Inc., with Bertek focusing on three therapeutic areas: dermatology, neurology, and cardiology. Other major brand name products include its first proprietary drug, Maxzide and Eldepryl for the treatment of Parkinson's disease.
|
